Journal: MedComm
Article Title: A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis
doi: 10.1002/mco2.70219
Figure Lengend Snippet: Study flow diagram. BD, bortezomib and dexamethasone; DBD, daratumumab, bortezomib, and dexamethasone.
Article Snippet: Anti‐plasma cell therapy was not used in this group due to denial by these patients for fear of side effects; group B received BD regimen including bortezomib (BSP Pharmaceuticals S.p.A, Italy) at a dose of 1.0 mg/m 2 injected subcutaneously, and dexamethasone (Chenxin Pharmaceutical Co., Ltd., China) at a dose of 10 mg injected intravenously, and both medications were used at Day 1, 4, 8, and 11 for one chemotherapy cycle; group C received DBD regimen involving daratumumab (Cilag AG, Switzerland) at a dose of 12 mg/kg injected intravenously, bortezomib at a dose of 1.0 mg/m 2 injected subcutaneously, and dexamethasone at a dose of 10 mg injected intravenously, and the three medications were used weekly for four times as one chemotherapy cycle.
Techniques: